1. 康哲药业
  2. 康哲药业
  3. 康哲药业

Business

Business Introduction


Pharmaceutical Business

Innovative Research

With more than two decades experience in introduction of and investment in global products, CMS has accumulated extensive overseas channel resources and market reputation, and established a unique and systematic product evaluation system. The Group acquires innovative products and technologies through industrial equity investment in innovative R&D companies or strategic cooperation with leading pharmaceutical companies around the world. The Group has made equity investments in a number of R&D companies from the U.K., France, Switzerland, the U.S., China, etc., and initiated a new model for industrial investment in innovative drugs, achieving combination of complementary advantages and strong alliance to accelerate the R&D and commercialization progress of innovative products. As at 31 December 2021, the Group has acquired nearly 30 innovative products with relatively high innovation level, good market potential and competitive differentiation advantages. Among them, 9 innovative products have been approved for marketing in the U.S. and/or Europe; new drug applications of 3 innovative products have been accepted, 2 innovative products obtained positive results from their bridging trials, and 3 innovative products obtained clinical trial approvals in China.

More>>

Products

Partners of Existing Products

CMS has created professional brand image and good sales records for a number of quality branded drugs in China, and received the high recognition from dozens of partners of existing products.

More>>

Innovative Research

CMS concentrates on innovative products that are global first-in-class or with the best efficacy, safety or cost-effectiveness in the class due to their innovative formulations or drug delivery systems, and has established an innovative pipeline with relatively high innovation level, good market potential and competitive differentiation advantages.

More>>

Dermatology & Medical Aesthetics

CMS has been deeply engaged in the field of skin health for many years, and has deployed a number of dermatology products with competitive differentiation advantages, such as Hirudoid (exclusive marketed product), Tildrakizumab Solution for Injection (innovative medicine under marketing application review in China); meanwhile, the Group has accumulated abundant sales and promotion resources in the dermatology field. As at 31 December 2020, the Group's sales and promotion network has covered more than 50,000 hospitals and medical institutions, over 200,000 retail pharmacies, and about 12,000 dermatologists, and has more than 500 professional dermatology promotion staff. In order to effectively utilize the sales and promotion channel resources and improve the efficiency in the dermatology field, the Group acquired Luqa Ventures (Luqa), a dermatology specialty company, on 1 February 2021, which has enriched the Group’s dermatology line and expanded the Group’s business boundary with its strengths to enter the medical aesthetic field.

More>>

Healthcare

Capitalizing on its strengths such as overseas channel resources accumulated for more than two decades, good reputation, unique product evaluation system, responsive global supply chain system, and strong promotion network, CMS stringently selects functional quality healthcare products with unique ingredients globally according to medical concept and high standards, and supplies the products to Mainland China through cross-border e-commerce platforms, so as to provide consumers with healthy lives.

More>>

Investor Relations

Announcements & Circulars

  • 2022-08-02
    Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 July 2022
  • 2022-07-26
    Voluntary and Business Update Announcement Acquisition of Ophthalmic Bispecific Antibody Product Assets
  • 2022-07-05
    Monthly Return of Equity Issuer on Movements in Securities for the month ended 30 June 2022
  • 2022-06-15
    Next Day Disclosure Return
  • 2022-06-02
    Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 May 2022
  • 2022-05-05
    Monthly Return of Equity Issuer on Movements in Securities for the month ended 30 April 2022
  • More>>

    Financial Reports

  • Annual Report 2021

  • Interim Report 2021

  • Annual Report 2020

  • Interim Report 2020

  • Annual Report 2019

  • Interim Report 2019

  • More>>

    Stock Quotes